ASCEND-4

NCT01828099 📎

Regimen

Experimental
ceritinib
Control
platinum+pemetrexed

Population

ALK+ advanced NSCLC 1L

Key finding

mPFS 16.6 vs 8.1 mo, HR 0.55 (0.42-0.73); confirmed 2nd-gen ALK TKI benefit

Source: PMID 28126333

Timeline

  • Enrollment start: 2013-07-09 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)
  • CSCO NSCLC 2025 ⚠️ OCR source